Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rowland

Showing results (831-840 of 924) with videos related to

Pageof 93
Sort By:
Journal of Clinical Microbiology|August 21, 2020
Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency UseHarry E Prince, Tara S Givens, Mary Lapé-Nixon, et al.
Cancer|January 29, 2008
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021Scott H Okuno, Robert Delaune, Jeff A Sloan, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 28, 2023
Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flowStephanie M Hare, Bhim M Adhikari, Chen Mo, et al.
Schizophrenia Bulletin|January 12, 2022
Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in SchizophreniaAnthony O Ahmed, Brian Kirkpatrick, Eric Granholm, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG studyThanyanan Reungwetwattana, Julian R Molina, Sumithra J Mandrekar, et al.
Haematologica|March 17, 2009
F9 Malmö, factor IX and deep vein thrombosisIrene D Bezemer, Andre R Arellano, Carmen H Tong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancerCynthia X Ma, Suresh Nair, Sachdev Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancerDavid P Steensma, Roy Molina, Jeff A Sloan, et al.
Cell|August 10, 2019
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus NeutralizationKathryn M Hastie, Robert W Cross, Stephanie S Harkins, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 15, 2012
The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9Debra L Barton, Kelli Burger, Paul J Novotny, et al.
Pageof 93

Showing results (831-840 of 924) with videos related to

Sort By:
Pageof 93
Journal of Clinical Microbiology|August 21, 2020
Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency UseHarry E Prince, Tara S Givens, Mary Lapé-Nixon, et al.
Cancer|January 29, 2008
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021Scott H Okuno, Robert Delaune, Jeff A Sloan, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 28, 2023
Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flowStephanie M Hare, Bhim M Adhikari, Chen Mo, et al.
Schizophrenia Bulletin|January 12, 2022
Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in SchizophreniaAnthony O Ahmed, Brian Kirkpatrick, Eric Granholm, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG studyThanyanan Reungwetwattana, Julian R Molina, Sumithra J Mandrekar, et al.
Haematologica|March 17, 2009
F9 Malmö, factor IX and deep vein thrombosisIrene D Bezemer, Andre R Arellano, Carmen H Tong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancerCynthia X Ma, Suresh Nair, Sachdev Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancerDavid P Steensma, Roy Molina, Jeff A Sloan, et al.
Cell|August 10, 2019
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus NeutralizationKathryn M Hastie, Robert W Cross, Stephanie S Harkins, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 15, 2012
The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9Debra L Barton, Kelli Burger, Paul J Novotny, et al.
Pageof 93